
## **Richard P Tobin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9043700/publications.pdf Version: 2024-02-01



RICHARD P TORIN

#	Article	IF	CITATIONS
1	IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Frontiers in Oncology, 2019, 9, 1223.	2.8	88
2	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers, 2020, 12, 2182.	3.7	21
3	MAIT Cells: Partners or Enemies in Cancer Immunotherapy?. Cancers, 2021, 13, 1502.	3.7	18
4	Circulating CD8 <sup>+</sup> mucosalâ€associated invariant T cells correlate with improved treatment responses and overall survival in antiâ€PD″â€treated melanoma patients. Clinical and Translational Immunology, 2022, 11, e1367.	3.8	16
5	High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell Changes. ImmunoHorizons, 2020, 4, 82-92.	1.8	6
6	Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 53-63.	4.9	6
7	Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma Journal of Clinical Oncology, 2021, 39, 9536-9536.	1.6	4
8	Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. Journal of Investigative Dermatology, 2022, 142, 1912-1922.e7.	0.7	3
9	BRAF Modulates Lipid Use and Accumulation. Cancers, 2022, 14, 2110.	3.7	3
10	Abstract PO048: Loss of intra-tumoral RIG-I immune signaling is a potential microbiome-mediated mechanism underlying poor anti-tumor immunity and immunotherapy resistance in mucosal melanoma. , 2021, , .		1
11	Targeting the RIG-I-like receptor signaling pathway to improve the efficacy of immunotherapy in mucosal and uveal melanoma Journal of Clinical Oncology, 2021, 39, e21593-e21593.	1.6	1